SUMMARY In chronic rheumatoid arthritis (RA), disease modifying drugs are used in an attempt to suppress the progressive damage to tissues and joints that is associated with active disease. Their success in achieving this goal is variable; responses vary from complete suppression of all signs and symptoms of RA to continued active disease, with progressive disability, despite prolonged therapy. Because disease activity almost always recurs after the therapy is stopped, early interruption of an effective therapy for any reason will make its benefit insignificant in a lifelong disease such as RA. Similarly, short-term sequential use of multiple disease modifying therapies is unlikely to be beneficial. The immediate problems with these therapies are substantial. In general, fewer than 50 'Y% of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months or longer to achieve maximum effects, those patients who are unable to continue the drug receive little benefit from it. Inevitable delayed side-effects, such as those associated with chronic corticosteroid therapy, may make the benefit/risk ratio unacceptable. Potential late lethal adverse effects, such as malignancy, weight the benefit/risk ratio to varying extents for individual patients, depending on the relative probability that the adverse effect will occur during the remainder of the patient's anticipated life span, and are of greater importance in younger patients. In that minority of patients who achieve remission or near remission and are able to tolerate a disease modifying treatment for many years, it is of truly significant benefit. We are still searching for a therapy that will reliably achieve this goal for most patients with RA. Rothermich and associates'89 started 97 patients in a prospective study of gold therapy. After an average of 12 years, 41 % were having sufficient clinical benefit to continue the drug. However, four to six years after the study was started, only 14 patients were continuing gold therapy, and two more had discontinued because of remission. Most stopped gold because of loss of benefit, or toxicity, or both simultaneously.
In the same report, Rothermich et al'89 examined 171 patients who started D-penicillamine after failing gold therapy and 53 % had stopped gold within the first year, more for toxicity than for lack of benefit. At the end of three years, only 20 % continued gold, somewhat fewer than Srinivasan's finding of 35 %.205 At the end of five years, only 9% were still taking gold. Of course, these figures are biased by the requirement that only patients who had stopped gold were counted; the analysis is completely retrospective and the population may not be representative. Nevertheless, the majority of these patients stopped gold for loss of benefit.
D-PENICILLAMINE
Several similar studies of D-penicillamine therapy have been reported recently. Kean et al"2 found that 47 % of 101 patients continued D-penicillamine after one year and 38 % after two years. The major reason for stopping therapy in the first year was toxicity. After two years, two patients were in remission, five in partial remission, and 31 had 75 % improvement.
Webley and Coomes"3 reported that 46 % of 1 14 patients continued penicillamine after an average of 101 months' treatment. Of the 62 withdrawals, 40 were for toxicity and 12 for lack of response. There were no differences in toxicity or improvement rates in patients receiving more or less than 600 mg daily, or in patients who had or had not had previous gold therapy. COMPARATIVE 
STUDIES
Husain and Runge96 evaluated the risks of termination of treatment with gold, penicillamine, hydroxychloroquine and levamisole using a life table analysis. The risks for termination of gold and penicillamine were similar to those reported above, while that for hydroxychloroquine (25 % in 12 months) was lower, and that for levamisole (57% in 12 months) higher than for the other two drugs. However, in another paper, the same group reported that the median termination time was 60 months for gold and 13 months for antimalarial compounds. Lack of efficacy was responsible for treatment termination in 41 % of the antimalarial group in this study in which treatment was frequently terminated for lack of response after three to six months of treatment.'83 Dwosh et al"6 randomly assigned patients with class II RA to azathioprine, gold or chloroquine. After six months of treatment, all three agents were comparable in terms of toxicity and clinical improvement. However, the chloroquine group did not maintain continued improvement beyond six months, while in the gold and azathioprine groups benefit continued for up to 44 months. On the other hand, Cade et al25 reported that 14 of 16 patients treated with azathioprine for two to five years achieved 100% work ability, although it took up to 32 months of treatment to achieve that maximum response. Furthermore' serial x-rays showed no progression of destruction after completion of the second year of therapy, even when followed for as long as eight years.
Risks
Only major risks will be evaluated here. It is obvious that patients who are forced to stop treatment because of temporary reversible rash, proteinuria, marrow suppression, drug induced hepatitis, etc, do not benefit from the drug, but these adverse reactions rarely shorten their life span or produce permanent damage.
DEATH
Davis4" has recently reviewed the undesirable effects of gold therapy. With current dosages, marrow aplasia is the most serious adverse effect. Over a seven-year period in Great Britain, 16 deaths related to gold therapy were founid, an estimated incidence of 1 6 deaths per 1(0 000 prescriptions. This figure suggests to Davis that gold is ten times more toxic than any other therapy used in Great Britain. Davis reviewed four studies, published in 1962, 1968, 1976, and 1977, reporting Induction of autoimmune diseases has been reported with penicillamine therapy for RA, and also for Wilson's disease. In addition, the renal lesions associated with gold induced proteinuria have the characteristics of an immune complex mediated nephropathy, and the agranulocytosis of levamisole appears to be immune mediated. We have also seen new autoimmune manifestations develop during the apparently successful treatment of RA with thoracic duct lymphocyte depletion. These observations suggest that, while correcting some disease related abnormalities of the immune system, we may perturb the system in such a way that other manifestations of autoimmune disease emerge in some patients.
Conclusions
For those patients who achieve remission with a DMARD and are able to tolerate it for many years, the benefit clearly is greater than the risk. Unfortunately, because most patients do not achieve optimal benefits, or must stop treatment for annoying sideeffects, our goal of favourably altering the course of their RA is not achieved. Except for the antimalarials, there appears to be a real, although small, risk of drug associated death with all of the available
